Article: Comparison of Metformin and Nicotinamide Riboside in Reducing Tissue Aging: Preclinical Findings

PrevNext
Healthy Aging & Longevity Preclinical

Comparison of Metformin and Nicotinamide Riboside in Reducing Tissue Aging: Preclinical Findings

Synopsis

Metformin (MET) and nicotinamide riboside (NR) both have potential anti-aging effects, but how they work in different tissues isn't fully clear. This study showed that MET and NR reduce signs of aging in human stem cells grown in the lab. In aged rats, both treatments lessened inflammation, fibrosis, and abnormal protein buildup in multiple organs. They also partially reversed age-related gene changes. Together, these results show that MET and NR can reduce aging features in cells and tissues, supporting their potential as anti-aging treatments.

Journal

Life Medicine

Share

Read more

Autoimmune Disease

Counteracting CD38-Induced NAD+ Depletion Reduces Multiple Organ Fibrosis: Preclinical Findings

SynopsisSystemic sclerosis (SSc) involves fibrosis in multiple organs, but its cause is not fully understood. NAD+ decline with age and disease, often due to increased CD38 activity (an NADase), ma...

Read more
Liver Disease

Combined Metabolic Activators Reduce Liver Fat by Boosting Mitochondria: Preclinical Findings

SynopsisWith NAFLD increasing globally and no approved treatments, researchers tested a combination of metabolic activators (including NAD+ precursor nicotinamide riboside, antioxidants, and amino ...

Read more